Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an announcement.
Shanghai Junshi Biosciences Co., Ltd. has announced the adjournment of its 2025 first extraordinary general meeting (EGM) to 29 September 2025. The meeting will address special resolutions regarding the proposed grant of H Share Options to Mr. Zhang Zhuobing and Dr. Yao Sheng, contingent upon the adoption of the 2025 H Share Option Incentive Scheme. This development is significant for stakeholders as it reflects the company’s ongoing efforts to incentivize key personnel, potentially impacting its strategic direction and market positioning.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the research, development, and commercialization of innovative therapies. The company is primarily involved in the production of monoclonal antibodies and other biologics, targeting various diseases including cancer and autoimmune disorders.
Average Trading Volume: 13,634,161
Technical Sentiment Signal: Buy
Current Market Cap: HK$49.61B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.